In a well-run drug trial, neither the patient nor the clinician knows who received the active compound. That blind is what separates a real effect from hope, expectation and the enthusiasm of the person handing out the pills.
Psychedelics break it. Within about half an hour, almost everyone in the room knows exactly which arm they are in.
This is called functional unblinding, and it is not a detail. It is the single hardest methodological problem in the field, and in July 2026 it finally got an official answer.
What It Already Cost
The clearest illustration is the one the field would rather forget.
In June 2024, an FDA advisory committee voted 10 to 1 against recommending approval of Lykos Therapeutics' MDMA-assisted therapy for PTSD. In August 2024 the agency issued a Complete Response Letter declining to approve it and requiring an additional Phase 3 trial. The concerns were not limited to unblinding — the FDA also cited trial conduct problems, incomplete cardiac safety data, and questions about how long the benefit lasts — but unblinding sat at the centre of them.
Lykos accepted the decision in October 2024 and cut roughly 75% of its workforce. As of May 2026 no resubmission date has been announced. A new Phase 3 trial is a multi-year undertaking.
It is worth being precise about what happened there, because it is widely misread. The FDA did not rule that MDMA does not work. It ruled that the evidence submitted could not be trusted to show whether it works, because too much of the apparent benefit might have come from participants knowing what they had taken.
What the Guidance Asks For
The FDA published draft guidance on psychedelic clinical investigations in June 2023. The final version arrived in July 2026, and it turns what had been an open methodological argument into a set of expectations.
Rather than mandating one design, it sets out a menu of countermeasures:
- Active placebos — a control that produces some noticeable subjective effect, instead of an inert pill that is obviously inert. The guidance suggests low doses of the psychedelic itself, or other psychoactive drugs that mimic part of the experience.
- Blinding questionnaires — asking both participants and staff to guess which arm they were in, on a rating scale, so that unblinding is measured rather than assumed away.
- Expectancy questionnaires — administered before randomisation and again at the end, capturing what people believed would happen to them.
- Central raters blinded to both treatment allocation and visit number — so the person scoring the outcome cannot infer the arm from context or from knowing this is the post-treatment visit.
The bar it sets for results is explicit. Findings must be, in the agency's words, "strongly persuasive and robust across study endpoints to overcome biases that may be introduced by functional unblinding."
The Idea Worth Understanding
The most interesting element is not a countermeasure at all. It is a complementary trial design: pairing a conventional placebo-controlled study with a dose-response study that uses no placebo whatsoever.
The logic is worth following. If a placebo group is the problem — because everyone can tell who is in it — then run a second study where there is no placebo to identify. Instead, compare a low dose against a higher one. Participants still cannot be meaningfully blinded, but if outcomes scale with dose in a consistent way, that pattern is difficult to explain through expectation alone. Expectation does not usually arrive in neat proportion to milligrams.
Neither study fully resolves the problem. Together they constrain it from two directions, which is a more honest description of what good evidence looks like here than any single perfect trial would be.
What This Does Not Mean
Guidance is not approval. Nothing in the July 2026 document approves any psychedelic compound for any indication, and no classic psychedelic is currently an FDA-approved medicine.
The wider regulatory picture has moved quickly and should not be over-read either. An executive order signed on 18 April 2026 directed the FDA to support development of psychedelic therapies for PTSD, depressive disorders and substance use disorder, and authorised national priority vouchers that compress review timelines. Within days, vouchers went to Compass Pathways for psilocybin in treatment-resistant depression, the Usona Institute for psilocybin in major depressive disorder, and Transcend Therapeutics for methylone in PTSD.
A priority voucher shortens how long a review takes. It does not lower the evidentiary standard, and it does not indicate an outcome. Separately, the FDA has allowed an early-phase study of noribogaine — an ibogaine derivative — to proceed, the first time a study of an ibogaine derivative has been permitted to go ahead. That is a Phase 1 milestone, not a treatment.
Faster review plus a harder methodological standard is a strange combination to hold in mind at once. But it is the actual state of the field: the door is opening sooner, and what has to be carried through it is heavier.
Why It Matters Outside the Labs
For anyone weighing these treatments personally, the unblinding problem has a practical translation.
When you read that a psychedelic trial produced a large effect, the honest question is not only how large, but how much of it could be explained by participants knowing what they took, in a setting built around expectancy, with therapists who believed in the treatment. Sometimes the answer is "not much." Sometimes nobody measured it.
After July 2026, sponsors are expected to measure it. That is a smaller headline than an approval, and a more durable one.
Sources
- FDA advisory committee vote on Lykos Therapeutics' midomafetamine for PTSD, June 2024; FDA Complete Response Letter, August 2024.
- Lykos Therapeutics restructuring announcement and acceptance of the FDA decision, October 2024; status as reported through May 2026.
- FDA, Psychedelic Drugs: Considerations for Clinical Investigations — draft guidance June 2023, finalised July 2026.
- Executive order on psychedelic therapy development, 18 April 2026, and subsequent FDA national priority voucher awards to Compass Pathways, the Usona Institute and Transcend Therapeutics.
- FDA clearance for an early-phase clinical study of noribogaine hydrochloride, 2026.
This article is for educational purposes only and does not constitute medical advice. No classic psychedelic is currently approved by the FDA as a medicine, and participation in clinical research carries risk. Discuss any treatment decision with a qualified clinician.